The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | MonumenTAL-1 update: talquetamab in R/R multiple myeloma
Ajai Chari, MD, PhD, Mount Sinai School of Medicine, New York City, NY, discusses updates from the Phase I/II MonumenTAL-1 trial (NCT03399799/NCT04634552) assessing talquetamab in patients with relapsed/refractory (R/R) multiple myeloma. Whilst the study reported promising response rates in each of the different doses tested, Dr Chari notes that patients experienced unusual off-target toxicities due to GPRC5D expression in normal tissues. Nevertheless, these adverse events were low grade and suggest talquetamab as a good candidate for combination therapies. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Paid Consultant for Janssen
